

Methodological Note

Annual Disclosure of Transfers of Value to Health Professionals, Other Relevant Decision Makers and Healthcare Organisations

Company	Syner-Med (PP) Ltd (Syner-Med Pharmaceutical Products Limited)
Reporting Year	2025 transfers of value, disclosed in 2026
Date of Publication	23/06/2026
Version	1.0

This methodological note is published in accordance with Clause 28.6 of the 2024 ABPI Code of Practice and the EFPIA Code on Disclosure of Transfers of Value, Annex B (2025 updated standardised structure). Syner-Med (PP) Ltd is not a member of the ABPI but has voluntarily agreed to abide by the ABPI Code of Practice in all aspects of its commercial and non-commercial activities.

1. Definitions

1.1 Recipients

Transfers of value disclosed in this report relate to the following recipient types:

- **Health Professionals (HCPs):** individuals who are members of the medical, dental, pharmacy or nursing professions, or any other person who in the course of their professional activities may prescribe, purchase, supply, recommend or administer a medicinal product.
- **Healthcare Organisations (HCOs):** any body corporate or unincorporated body other than a pharmaceutical company or a government or regulatory authority, that is a legally recognised entity under which one or more health professionals provide healthcare or conduct research.

Syner-Med did not make transfers of value to Other Relevant Decision Makers (ORDMs) during the 2025 reporting period.

Transfers of value to retired HCPs are managed in the same manner as active HCPs and disclosed accordingly. In the event of the death of a recipient, data is managed in accordance with PMCPA guidance on deceased health professionals; the company removes or does not publish the individual's name whilst retaining the associated transfer of value in the disclosure.

1.2 Kind of Transfers of Value (ToVs)

The following categories of transfer of value are applicable to Syner-Med's 2025 disclosures:

- **Contracted Service Fees:** fees paid to HCPs for services rendered under a written contract (e.g. speaker services, advisory board participation, consultancy).

- Expenses: reimbursement of reasonable and actual travel, accommodation and meal expenses incurred by HCPs in connection with contracted services.

No donations, grants, contributions to costs of events, research and development payments, or transfers of value to HCOs were made during the 2025 reporting period.

2. Disclosure's Scope

2.1 Products Concerned

Disclosures relate solely to Prescription Only Medicines (POMs) promoted or distributed by Syner-Med (PP) Ltd in the United Kingdom. Over-the-counter medicines and medical device transfers of value are not included in this disclosure.

2.2 Company Concerned

This methodological note covers Syner-Med (PP) Ltd, trading as Syner-Med Pharmaceutical Products Limited, a company registered in England and Wales (Registration No: 2950518), with its registered office at Castle Court, 41 London Road, Reigate, Surrey, RH2 9RJ.

Syner-Med has no subsidiaries, affiliates, or group companies whose UK transfers of value are captured within this disclosure. Each entity would disclose independently if applicable.

The company has not changed its name or undergone any merger or acquisition during the 2025 reporting period.

2.3 Excluded ToVs

The following categories of transfer of value have been excluded from disclosure in accordance with the ABPI Code (Clause 1.25):

- Items of medical utility or educational materials of insignificant value.
- Transfers of value made in the context of research and development that are subject to separate R&D disclosure rules (none applicable in 2025).

2.4 ToVs Date

This disclosure covers transfers of value made by Syner-Med during the calendar year 1 January 2025 to 31 December 2025, inclusive. The recognition date applied is the date on which the transfer of value was made (i.e. date of payment or delivery of service), not the date of contract signature.

2.5 Direct ToVs

Direct transfers of value are those made by Syner-Med directly to the HCP or HCO, without the involvement of a third-party intermediary. For the 2025 reporting period, direct transfers of value include:

- Contracted speaker service fees paid directly to HCPs for participation in educational and promotional webinars in the therapeutic areas of Nephrology and Vascular Access.

2.6 Indirect ToVs

Not applicable.

Syner-Med did not make any indirect transfers of value (i.e. via third-party event organisers or other intermediaries) during the 2025 reporting period.

2.7 Non-Monetary ToVs

Not applicable.

No non-monetary transfers of value (e.g. staff time, equipment, or in-kind services) were made during the 2025 reporting period.

2.8 ToVs in Case of Partial Attendance or Cancellation and Refund

Where an HCP attended only part of an event, the fee payable was pro-rated based on actual time spent delivering contracted services, as specified in the relevant service agreement. In the event of cancellation by the HCP prior to delivery of services, no fee was payable. Any fees already paid in respect of cancelled engagements were recovered or offset. No refunds to HCPs were required during the 2025 reporting period.

2.9 Cross-Border Activities

Not applicable.

All transfers of value during the 2025 reporting period were made to UK-based HCPs in connection with UK activities. No cross-border transfers of value were made.

2.10 Research and Development (R&D)

Not applicable.

Syner-Med did not engage in any transfers of value that fall within the R&D category as defined in the ABPI Code during the 2025 reporting period.

2.11 Voluntary Disclosure

Syner-Med (PP) Ltd is not a member of ABPI but has voluntarily agreed to abide by the ABPI Code of Practice in all aspects of its commercial and non-commercial activities. The disclosures made are in accordance with the mandatory requirements of the ABPI Code (Clauses 28–31) and do not go beyond what is required. No voluntary disclosures beyond the Code requirements are included.

3. Specific Considerations

3.1 Country Unique Identifier

Syner-Med does not use publicly available professional identifiers or commercial identifiers. HCPs are recorded and tracked using an internal log maintained by the company, which captures sufficient information to ensure accurate identification and avoid duplication in disclosures.

3.2 Self-Incorporated HCP

Where an HCP provides services through a Limited company (a personal service company), Syner-Med assesses whether the payment should be attributed to the individual HCP or the company entity, in line with Clauses 1.8 and 1.25 of the ABPI Code. In 2025, all contracted service fees were paid directly to individual HCPs and not through personal service companies.

3.3 Multi-Year Agreements

Where a multi-year agreement exists, only the transfers of value actually delivered or paid during the 2025 calendar year are recognised and disclosed for the 2025 reporting period. Future years' values under such agreements are not accrued or pre-disclosed. There were no multi-year agreements resulting in transfers of value during the 2025 reporting period.

3.4 Country Specificities

Syner-Med did not engage in any collaborative working projects with other pharmaceutical companies during the 2025 reporting period. Accordingly, no allocation of transfers of value between parties was required, and no collaborative working executive summaries are applicable.

3.5 Quality Checks

Prior to submission of 2025 data to Disclosure UK, Syner-Med undertook the following internal quality assurance steps:

1. Review of all payment records against signed contracts to confirm accuracy of amounts and recipient details.
2. Confirmation that all HCPs included in the disclosure provided written consent for individual named disclosure prior to data submission.
3. Cross-check of disclosed values against finance records to ensure completeness and accuracy.
4. Review by the Medical and Clinical Advisor sign-off prior to publication.

4. Data Protection Legal Basis

4.1 Consent Collection

The lawful basis used for publishing individual HCP information (named disclosure) is consent, in accordance with the UK General Data Protection Regulation (UK GDPR) and Clause 28.5 of the ABPI Code.

All four HCPs included in the 2025 individual disclosure provided written consent to Syner-Med prior to data submission. HCPs were informed of the purpose of disclosure and the platform on which data would be published (Disclosure UK). No HCP agreed to partial disclosure (i.e. some payments individual and some in aggregate) during the 2025 reporting period; all consenting HCPs agreed to full individual named disclosure.

Withdrawal of consent is managed by contacting Syner-Med's designated data protection contact. In the event of withdrawal, the company will take reasonable steps to remove or

anonymise the relevant data from public disclosure, subject to Disclosure UK's platform capabilities and any applicable legal obligations.

4.2 Legitimate Interests

Not applicable.

Syner-Med relies on consent (Section 4.1 above) as the lawful basis for all individual named disclosures. Legitimate interests is not used as the legal basis for any disclosure in the 2025 reporting period.

5. Form of Disclosure

5.1 Date of Publication	23/06/2026
5.2 Disclosure Platform	Disclosure UK – www.disclosureuk.org.uk
5.3 Disclosure Language	English

6. Disclosure Financial Data

6.1 Currency

All transfers of value are disclosed in Pounds Sterling (GBP). All payments during the 2025 reporting period were made in GBP; no foreign currency conversions were required.

6.2 VAT Included or Excluded

Transferred values are disclosed exclusive of VAT (ex-VAT). Where applicable, VAT was charged and paid in accordance with applicable UK tax rules, but is not included in the disclosed amounts. No other tax considerations affect the disclosed values for the 2025 reporting period.

6.3 Calculation Rules

Contracted service fees are disclosed at the agreed contractual rate, reflecting actual time spent on contracted activities, pro-rated where applicable (see Section 2.8). Expense reimbursements are disclosed at actual cost based on receipts submitted. No in-kind or non-monetary transfers of value were made during the 2025 reporting period; accordingly, no valuation methodology for non-monetary values was required.

7. Additional Information

Syner-Med (PP) Ltd is not a member of ABPI but has voluntarily agreed to abide by the ABPI Code of Practice. This methodological note is submitted and published via Disclosure



UK in accordance with Clause 28.6 of the 2024 ABPI Code and the EFPIA standardised methodological note structure (Annex B, 2025 update).

For any queries regarding this methodological note or the associated disclosures, please contact:

Contact Name	Prashan Bhatti
Title	Medical and Clinical Advisor
Email	prashanb@synermed.com
Direct Line	+44 7802 689789
Company Address	Syner-Med Pharmaceutical Products Limited, Castle Court, 41 London Road, Reigate, Surrey, RH2 9RJ, United Kingdom

